Institutional members access full text with Ovid®

Share this article on:

Fractionated Radiation Therapy for Benign Nonacoustic Schwannomas

Kharod, Shivam, M., BS; Herman, Michael, P., MD; Amdur, Robert, J., MD; Mendenhall, William, M., MD

American Journal of Clinical Oncology: January 2018 - Volume 41 - Issue 1 - p 13–17
doi: 10.1097/COC.0000000000000219
Original Articles: Central Nervous System

Objectives: We analyzed the outcomes of patients with benign nonacoustic schwannomas treated with fractionated radiation therapy (RT).

Methods: Between October 1987 and March 2013, 11 patients with benign nonacoustic schwannomas diagnosed radiographically (n=3) or pathologically (n=8) were treated with fractionated RT with curative intent at the University of Florida. We reviewed patients’ medical records to assess outcomes and toxicities from treatment.

Results: The median follow-up for all patients was 8.2 years (range, 2.2 to 22.7 y) and 8 years for all living patients (range, 2.2 to 22.7 y). Of the 11 patients included in the analysis, 8 (73%) were treated solely with RT, 1 (9%) was treated with postoperative RT after subtotal resection, and 2 (18%) were treated with postoperative RT after recurrence following initial surgical resection. The 5-year overall survival, disease-free survival, and local control rates were 100%. There were no grade 2 to 5 treatment toxicities.

Conclusions: RT for benign nonacoustic schwannoma may be effective when used alone or in addition to surgery. Irradiation should be considered in patients for whom resection is likely to result in one or more neurological deficits. Fractionated RT to a total dose of 50 Gy provides excellent local control and minimal morbidity.

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL

The authors declare no conflicts of interest.

Reprints: William M. Mendenhall, MD, 2000 SW Archer Rd., PO Box 100385, Gainesville, FL 32610-0385. E-mail:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.